Pancreatic Cancer Research

ResearcherUniversità Cattolica del Sacro CuoreActive in the last 2 years

Giampaolo Tortora

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-1378-4962; OpenAlex author ID A5050215401, A5078862969, A5130630722. Sources: OpenAlex.

Their work

Papers
55 (first author 1, last author 12)
Trials
0
Grants
0
Labs led
2
Collaborators
181
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: 2 papers · 2016: 1 paper · 2017: 2 papers · 2018: 5 papers · 2019: 2 papers · 2020: none · 2021: 7 papers · 2022: 3 papers · 2023: 8 papers · 2024: 8 papers · 2025: 5 papers · 2026: 8 papers

Papers 50 of 55

  1. Designing a national network of pancreas units: the Italian model for high-quality pancreatic cancer care. Co-author DOI 10.1007/s13304-026-02598-7↗
  2. Impact of diabetes mellitus on treatment efficacy in patients with advanced pancreatic cancer: the Italian, multicenter, observational PANCAKE study. Co-author DOI 10.1016/j.esmogo.2025.100276↗
  3. Prognostic impact of Geriatric 8 and comprehensive geriatric assessment in older patients with advanced pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.jgo.2025.102782↗
  4. Response to letter to the Editor: Geriatric assessment and sarcopenia in pancreatic cancer: Toward personalized treatment beyond chronological age. Last author DOI 10.1016/j.jgo.2026.102890↗
  5. Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection. Co-author DOI 10.1093/oncolo/oyag085↗
  6. Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 St… Co-author DOI 10.1158/2767-9764.crc-26-0018↗
  7. Increased cytotoxic effects via combined treatment of magnetic field and radiation therapy in patient-derived organoids of pancreatic ductal adenocarcinoma Co-author DOI 10.21203/rs.3.rs-9009316/v1↗
  8. Transcriptional and Epigenetic Plasticity Drive an Alternative Non-clonal Mechanism of Resistance to Kras G12D Inhibition in Pancreatic Cancer Co-author DOI 10.34133/cancomm.0030↗
  9. Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants. Co-author DOI 10.1002/cam4.70364↗
  10. Local ablation disrupts immune evasion in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2024.217327↗
  11. Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine-nab-paclitaxel failure: a propensity score… Last author DOI 10.1016/j.esmoop.2025.105874↗
  12. Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pancreatic ductal adenocarcinoma syngeneic… Last author DOI 10.1186/s13046-024-03238-x↗
  13. The GLP-1R agonist semaglutide reshapes pancreatic cancer associated fibroblasts reducing collagen proline hydroxylation and favoring T lymphocyte infiltration. Co-author DOI 10.1186/s13046-024-03263-w↗
  14. Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment. Co-author DOI 10.1002/cam4.7345↗
  15. Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients. Co-author DOI 10.1016/j.ejca.2024.114226↗
  16. An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2024.101411↗
  17. Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-… Co-author DOI 10.1016/s1470-2045(24)00511-4↗
  18. Weighted gene co-expression network analysis reveals key stromal prognostic markers in pancreatic cancer. Co-author DOI 10.1038/s41598-024-82563-9↗
  19. Preoperative low skeletal muscle mass index assessed using L3-CT as a prognostic marker of clinical outcomes in pancreatic cancer patients undergoing surgery: … Co-author DOI 10.1097/js9.0000000000000989↗
  20. Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarci… Co-author DOI 10.1186/s12885-024-12936-w↗
  21. Combined Nabpaclitaxel pressurized intraPeritoneal aerosol chemotherapy with systemic Nabpaclitaxel-Gemcitabine chemotherapy for pancreatic cancer peritoneal m… Last author DOI 10.1515/pp-2024-0010↗
  22. Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA… Co-author DOI 10.1007/s00280-023-04585-w↗
  23. Clinical and genomic characterization of pancreatic ductal adenocarcinoma patients with lung oligometastasis. Co-author DOI 10.1016/j.esmogo.2023.08.010↗
  24. CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer. Last author DOI 10.1038/s41416-022-02028-6↗
  25. Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv). Co-author DOI 10.1038/s41416-022-02086-w↗
  26. Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer. Co-author DOI 10.1186/s12967-023-04733-z↗
  27. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  28. KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy. Last author DOI 10.3390/ijms24119313↗
  29. Nutritional Interventions during Chemotherapy for Pancreatic Cancer: A Systematic Review of Prospective Studies. Co-author DOI 10.3390/nu15030727↗
  30. Role of Chemoradiation in the Adjuvant Treatment of Radically Resected Pancreatic Cancer Patients: A Mono-Institutional Retrospective Analysis. Co-author DOI 10.1159/000525945↗
  31. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic C… Co-author DOI 10.1200/jco.21.01604↗
  32. Spatial transcriptomics identified mucin-specific O-glycosylation as a key pathway in pancreatic cancer development and a promising therapeutic target Co-author DOI 10.21203/rs.3.rs-2095432/v1↗
  33. Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. Co-author DOI 10.1016/j.esmoop.2020.100032↗
  34. Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter surve… Co-author DOI 10.1016/j.esmoop.2021.100238↗
  35. Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with a… Last author DOI 10.1136/jitc-2021-002876↗
  36. Pancreatic Cancer Patient-Derived Organoid Platforms: A Clinical Tool to Study Cell- and Non-Cell-Autonomous Mechanisms of Treatment Response. Last author DOI 10.3389/fmed.2021.793144↗
  37. Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.688889↗
  38. Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study). Co-author DOI 10.3390/curroncol28030164↗
  39. Neoadjuvant treatment: A window of opportunity for nutritional prehabilitation in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.4240/wjgs.v13.i9.885↗
  40. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. Co-author DOI 10.1056/nejmoa1903387↗
  41. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. Co-author DOI 10.1093/annonc/mdz406↗
  42. Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling. Co-author DOI 10.1038/ijo.2017.285↗
  43. Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy. Last author DOI 10.1038/s41430-018-0155-5↗
  44. An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the… Last author DOI 10.1080/14737167.2018.1464394↗
  45. MEKK3 Sustains EMT and Stemness in Pancreatic Cancer by Regulating YAP and TAZ Transcriptional Activity. Co-author DOI 10.21873/anticanres.12431↗
  46. Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance. Co-author DOI 10.3390/ijms19113331↗
  47. Hypermutation In Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2016.09.060↗
  48. A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma. Co-author DOI 10.1080/2162402x.2017.1322242↗
  49. Genomic analyses identify molecular subtypes of pancreatic cancer. Co-author DOI 10.1038/nature16965↗
  50. Whole genomes redefine the mutational landscape of pancreatic cancer. Co-author DOI 10.1038/nature14169↗

Closest collaborators

The 25 strongest of 181 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lisa Salvatore · 16 shared papers, 2018–2026 · strength 3.01
  2. Carmine Carbone · 18 shared papers, 2013–2026 · strength 2.60
  3. Geny Piro · 15 shared papers, 2013–2026 · strength 2.02
  4. Antonio Agostini · 11 shared papers, 2021–2026 · strength 1.88
  5. Michele Reni · 13 shared papers, 2018–2026 · strength 1.59
  6. Vincenzo Corbo · 9 shared papers, 2012–2026 · strength 1.39
  7. Sergio Alfieri · 9 shared papers, 2021–2026 · strength 1.37
  8. Michèle Milella · 11 shared papers, 2011–2026 · strength 1.30
  9. Guido Giordano · 9 shared papers, 2021–2026 · strength 1.21
  10. Monica Niger · 8 shared papers, 2021–2026 · strength 1.19
  11. Giovanni Trovato · 4 shared papers, 2024–2026 · strength 1.14
  12. Giuseppe Quero · 7 shared papers, 2021–2026 · strength 1.06
  13. Francesco De Sanctis · 6 shared papers, 2021–2026 · strength 1.01
  14. Elisa Giommoni · 7 shared papers, 2021–2026 · strength 0.97
  15. Mario Scartozzi · 6 shared papers, 2021–2026 · strength 0.96
  16. Davide Melisi · 11 shared papers, 2011–2026 · strength 0.96
  17. Letizia Procaccio · 6 shared papers, 2023–2026 · strength 0.95
  18. Marina Macchini · 7 shared papers, 2021–2025 · strength 0.92
  19. Giulia Orsi · 7 shared papers, 2021–2025 · strength 0.86
  20. Alessia Caggiano · 5 shared papers, 2022–2026 · strength 0.86
  21. Stefano Cascinu · 7 shared papers, 2018–2025 · strength 0.83
  22. Aldo Scarpa · 7 shared papers, 2012–2025 · strength 0.77
  23. Claudio Sette · 4 shared papers, 2021–2026 · strength 0.74
  24. Caterina Vivaldi · 4 shared papers, 2021–2026 · strength 0.71
  25. Mariacristina Di Marco · 5 shared papers, 2021–2026 · strength 0.66

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.